Skip to Content

Tag: CPAP Therapy


Providers

Quipt Home Medical sees ‘accelerating momentum’ 

May 17, 2022HME News Staff

CINCINNATI – Quipt Home Medical reported revenue of $33.6 million for the second quarter of fiscal year 2022, a 38% increase over the same period last year.  It reported net income of $5 million vs. a net loss of $12.5 million.  “We are extremely proud of the robust results we experienced in our fiscal second quarter, which showed accelerating momentum across our heavily weighted respiratory product mix as the quarter progressed,” said CEO and Chairman Greg Crawford....

CPAP Therapy, Financial Results, Quipt Home Medical


Read Full Articlered right arrow icon

Specialty Providers

Quipt buys Good Night

April 19, 2022HME News Staff

CINCINNATI – Quipt Home Medical has acquired Good Night Medical, a business with operations across seven states, for about $7 million in cash.  The acquisition provides Quipt Home Medical with expansion opportunities into Massachusetts, North Carolina and Texas, where it doesn’t have a presence.  “Good Night Medical strengthens our healthcare network across multiple states, enhancing our national coverage sphere over an area that includes about 5 million COPD sufferers...

CPAP Therapy, Good Night Medical, M&A, Quipt Home Medical, Respiratory Therapy


Read Full Articlered right arrow icon

Woody O'Neal

Specialty Providers

CPAP therapy has become less efficient

April 8, 2022Theresa Flaherty, Managing Editor

YARMOUTH, Maine – With HME providers struggling to obtain CPAP devices, payers should consider suspending compliance requirements, they argue.  Current Medicare guidelines call for patients to use their CPAP machines for at least four hours per night at least 70% of the time within any given time frame.  “It’d be great if they did, but I don’t have much hope any payer is going to,” said Woody O’Neal, vice president of Pelham, Ala.-based O2 Neal...

compliance requirements, CPAP Therapy


Read Full Articlered right arrow icon

News

In brief: CPAP preferences shift, Belluscura snags gov’t contract, CMS invests in home care 

April 8, 2022HME News Staff

NEW YORK – HME providers expect to shift an average of 58.4% of their Philips Respironics flow generator purchases and an average of 30.2% of their mask purchases to other companies due to the recall, according to the first quarter HME Sleep and Oxygen Survey from Needham.  That’s up from the 56% and 23.1%, respectively, reported in the third quarter survey.  “ResMed should gain market share over the (next 12 months),” the survey states. “Respondents...

Belluscura, CPAP recall, CPAP Therapy, Money Follows the Person, Portable Oxygen Concentrator


Read Full Articlered right arrow icon

Also Noted

Study: CPAP for elderly patients not as effective

February 23, 2022HME News Staff

COLUMBIA, Mo. – CPAP therapy may not be as effective for patients older than 80, say researchers from the University of Missouri School of Medicine. In a study published in Sleep Medicine, researchers studied 369 participants over the age of 70 with OSA and assigned roughly half to receive CPAP therapy for three months. Researchers used several metrics to compare both groups, including a subjective measure of a patient’s sleepiness, the effect of CPAP on sleep-related quality of life,...

CPAP Therapy, Dr. David Gozal, Sleep Apnea


Read Full Articlered right arrow icon

Josh Marx

Providers

Medical Service Company creates pathway to compliance

November 23, 2021Theresa Flaherty, Managing Editor

ATLANTA – With 70% of patient outreach calls going to “voice mail hell,” Medical Service Company knew it needed to revamp its PAP adherence program to boost patient engagement and compliance, and create better efficiencies.  So, the company set out to create an automated, scalable program using not only voice calls but also texts and emails, based on preference, to assess patients and evaluate factors that affect outcomes.  “So much of our process was to ask...

Automation, Compliance, CPAP Therapy, Medical Service Company


Read Full Articlered right arrow icon

Jim Hollingshead

Vendors

ResMed buys HST company

October 4, 2021HME News Staff

SAN DIEGO – ResMed has bought Ectosense, which makes the NightOwl home sleep test.  The NightOwl, approved by the U.S. Food and Drug Administration, is currently sold in the United States, Australia, New Zealand, India and parts of Europe. ResMed has distributed the NightOwl, under the brand ResMed onesleeptest, in Australia, New Zealand and India since 2020, and has been a minority investor in Ectosense since July 2020.  "Sleep labs and home tests each have critical roles to...

CPAP Therapy, Ectosense, Home Sleep Testing, NightOwl, Obstructive Sleep Apnea, ResMed


Read Full Articlered right arrow icon

Vendors

Philips: Don't use bacteria filters with CPAPs

August 12, 2021HME News Staff

CAMBRIDGE, Mass. – Philips does not recommend using bacteria filters with CPAP/BiLevel devices as a means of mitigating chemical emission or particulate matter, it says in a new document related to a recent recall.  “Due to an influx of questions, additional information is being provided about the use of bacteria filters with CPAP/BiLevel devices,” the company states. “According to FDA regulation 868.5260, bacteria filters are medical devices that are intended to remove...

bacteria filters, CPAP Therapy, Philips Recall


Read Full Articlered right arrow icon

News

Philips recall: AASM calls for support from CMS, payers

June 24, 2021HME News Staff

DARIEN, Ill. – The American Academy of Sleep Medicine and other professional organizations are making the case to CMS and private payers that the 90-day adherence rule for PAP therapy should be temporarily suspended in the wake of the Philips recall.  “Given that many patients will be affected by the recall, we are requesting support from CMS and private payers to temporarily suspend the 90-day adherence rule to allow patients to have existing equipment repaired or receive new...

Adherence Rule, American Academy of Sleep Medicine, CPAP Therapy, Philips Recall


Read Full Articlered right arrow icon

News

Draft assessment questions impact of CPAP therapy

April 19, 2021HME News Staff

WASHINGTON – Published studies mostly do not support that CPAP therapy affects long-term, clinically important outcomes, according to a 155-page draft technology assessment prepared for the Agency for Healthcare Research and Quality at the U.S. Department of Health and Human Services.  Specifically, with low strength of evidence, randomized controlled trials do not demonstrate that CPAP therapy affects all-cause mortality, various cardiovascular outcomes, changes in psychological measures...

CPAP Therapy, Evidence Review, Outcomes


Read Full Articlered right arrow icon